1. Poland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bioton S.a.

Bioton S.a.

BIO.WA
Bioton S.a.PL flagWarsaw Stock Exchange
4.04
PLN
- -
- -
346.46MMarket Cap
Bioton S.a.
BIO.WA
(Warsaw Stock Exchange)

Recent

price

4.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.12
5.14
5.69
4.03
4.39
3.87
3.23
4.21
2.81
2.35
2.58
1.9
2.72
2.12
2.42
3.29
3.09
Revenue per Share
2.08
-1.38
0.53
-0.08
0.04
-6.09
-0.33
-0.23
0.31
-1.48
0.4
0.03
0.02
0.03
-0.18
0.04
-0.12
Basic EPS, GAAP
-0.34
-1.96
0.52
0.22
0.16
-0.05
-0.01
-0.19
-0.18
-0.08
0.43
-0.09
0.31
-0.05
0.29
0.11
0.26
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
19.28
18.85
19.43
17.32
17.17
9.74
9
8.7
8.62
7.17
7.56
7.38
7.38
7.4
7.22
7.26
7.19
Book Value per Share
8.79
4.57
3.13
3.13
3.27
3.79
3.87
3.64
3.59
2.43
2.84
2.82
2.75
2.76
2.89
3.11
2.9
Tangible Book Value per Share
53
56
71
85
86
86
86
86
86
86
86
86
86
86
86
86
86
Basic Weighted Avg Shares
379
289
406
340
377
333
278
362
241
202
222
163
233
182
208
283
265
Sales/Revenue/Turnover
20.43
-19.78
15.57
3.25
4.99
5.83
-6.17
1.09
-20.78
-7.89
23.96
7.74
11.16
-1.68
-2.78
4.92
1.5
Operating Margin (%)
39
37
36
30
34
37
35
33
29
32
32
32
34
35
36
38
38
Depreciation Expense
111
-78
38
-6
4
-523
-29
-20
26
-127
34
3
1
2
-16
3
-10
Net Income, GAAP
7.03
- -
50.42
95.57
44.53
- -
- -
- -
- -
- -
18.48
65.41
71.3
68.55
- -
56.67
89,237.12
Effective Tax Rate (%)
29.25
-26.84
9.31
-1.89
0.97
-157.22
-10.29
-5.57
10.89
-62.71
15.29
1.77
0.61
1.25
-7.54
1.2
-3.92
Profit Margin (%)
215
29
-128
10
67
23
23
-6
-23
-60
-6
9
12
1
11
42
17
Working Capital
114
126
17
112
98
59
48
23
18
48
39
29
19
13
14
21
14
LT Debt
1,171
1,389
1,337
1,385
1,446
807
788
735
713
585
620
605
604
606
591
594
588
Total Equity
5.4
- -
1.97
0.03
0.64
- -
- -
- -
- -
- -
5.94
0.6
1.06
-0.14
- -
0.92
- -
Return on Invested Capital (%)
10.92
- -
2.72
-0.34
0.82
- -
- -
- -
- -
- -
5.07
0.59
0.51
0.69
- -
0.82
423.83
Return on Capital (%)
14.67
-7.44
3.09
-0.45
0.25
-45.26
-3.55
-2.65
3.53
-18.7
5.36
0.45
0.22
0.36
-2.49
0.55
-1.67
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
43
37
32
LT Borrowings
- -
- -
- -
LT Finance Leases
14
13
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
86
86
Market Capitalization
248
314
350

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
154
134
133
Cash, Cash Equivalents & STI
7
3
1
Accounts Receivable, Net
27
32
35
Inventories
105
95
88
Total Current Liabilities
143
126
116
Payables & Accruals
- -
- -
- -
ST Debt
43
37
32
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.82%
-0.83%
0.58%
Free Cash Flow
-102.4%
-282.44%
-62%
Net Income, GAAP
-205.56%
-198.4%
-121.67%
Sales/Revenue/Turnover
1.88%
8.96%
35.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37
51
42
78
208
2025
66
80
64
- -
283
2026
49
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
- -
-0.04
-0.05
-0.18
2025
-0.07
- -
0.02
- -
0.04
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cline Scientific AB (publ) (CLINE-B.ST)
Hard to Treat Diseases Inc. (HTDS)
Oncternal Therapeutics, Inc. (ONCT)
enGene Holdings Inc. Warrants (ENGNW)
GeoVax Labs, Inc. (GOVX)
Kaleido Biosciences, Inc. (KLDO)
Business
Bioton SA (BIO.WA) is a Poland-based biotechnology company that develops, manufactures, markets and sells recombinant human insulin and related pharmaceutical products; provides contract development and manufacturing organization (CDMO) services including process development, analytical testing, technology transfer and GMP-compliant production of recombinant proteins and peptides; and offers innovative gastroenterological foods for special medical purposes (FSMP) alongside diabetes care solutions such as insulin analogs, oral antidiabetics, medical devices and digital health platforms. Founded in 1989 and headquartered in Ożarów Mazowiecki near Warsaw, the company operates primarily in Poland with exports to 35 countries including China, Russia, Thailand and Egypt, positioning it as a leader in the Polish diabetes market and among the world's top eight producers of recombinant human insulin. In June 2025, Bioton signed a memorandum of understanding with The Heart to collaborate on R&D pipeline expansion in biotechnology production, diabetology and gut health innovations; in October 2024, it secured a production agreement with a global pharmaceutical company for recombinant human insulin; and it continues to invest in modernizing its Macierzysz manufacturing site while enhancing CDMO capabilities through scale-down model laboratories and QbD-compliant processes.